Cargando…
Biomarkers for glioblastoma multiforme: status quo
BACKGROUND: Glioblastoma (GBM) is the most frequent and most malignant central nervous system (CNS) tumor. GBM shows poor prognosis with a median overall survival of 14.6 months, despite current surgical and adjuvant therapies. O(6)-methylguanine-DNA methyltransferase (MGMT) methylation is the stron...
Autores principales: | Montano, Nicola, D’Alessandris, Quintino Giorgio, Izzo, Alessandro, Fernandez, Eduardo, Pallini, Roberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Whioce Publishing Pte. Ltd.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410643/ https://www.ncbi.nlm.nih.gov/pubmed/30873456 |
Ejemplares similares
-
Neuromodulation for Brain Tumors: Myth or Reality? A Narrative Review
por: D’Alessandris, Quintino Giorgio, et al.
Publicado: (2023) -
Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome
por: Cesarini, Valeriana, et al.
Publicado: (2017) -
The importance of pre-operative neuroanatomical study in the surgical treatment of trigeminal neuralgia associated with multiple sclerosis
por: Montano, Nicola, et al.
Publicado: (2023) -
The role of artificial intelligence in the management of trigeminal neuralgia
por: Battistelli, Marco, et al.
Publicado: (2023) -
VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma
por: Martini, Maurizio, et al.
Publicado: (2018)